Cancer incidence, survival and mortality: Explaining the concepts

Cancer incidence, survival and mortality are essential population‐based indicators for public health and cancer control. Confusion and misunderstanding still surround the estimation and interpretation of these indicators. Recurring controversies over the use and misuse of population‐based cancer statistics in health policy suggests the need for further clarification. In our article, we describe the concepts that underlie the measures of incidence, survival and mortality, and illustrate the synergy between these measures of the cancer burden. We demonstrate the relationships between trends in incidence, survival and mortality, using real data for cancers of the lung and breast from England and Sweden. Finally, we discuss the importance of using all three measures in combination when interpreting overall progress in cancer control, and we offer some recommendations for their use.

[1]  P. Autier,et al.  Caution needed for country-specific cancer survival , 2011, The Lancet.

[2]  Paul C Lambert,et al.  Flexible parametric models for relative survival, with application in coronary heart disease , 2007, Statistics in medicine.

[3]  P. Whelan.  Survival from bladder cancer in England and Wales up to 2001 , 2008, British Journal of Cancer.

[4]  Hermann Brenner,et al.  Multiple tumours in survival estimates. , 2009, European journal of cancer.

[5]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[6]  W. Anderson,et al.  Cancer survival statistics should be viewed with caution. , 2007, The Lancet. Oncology.

[7]  M. Coleman,et al.  Rebuttal to editorial saying cancer survival statistics are misleading , 2011, BMJ : British Medical Journal.

[8]  J. Estève,et al.  Statistical methods in cancer research. Volume IV. Descriptive epidemiology. , 1998, IARC scientific publications.

[9]  Sabine Siesling,et al.  Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. , 2008, European journal of cancer.

[10]  L. Ellison.  Measuring the effect of including multiple cancers in survival analyses using data from the Canadian Cancer Registry. , 2010, Cancer epidemiology.

[11]  B Rachet,et al.  Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data , 2011, Lancet.

[12]  J. Coebergh,et al.  Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study. , 2007, European journal of cancer.

[13]  Paul C. Lambert,et al.  Further Development of Flexible Parametric Models for Survival Analysis , 2009 .

[14]  Steve Scoppa,et al.  Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship , 2007, Cancer Epidemiology Biomarkers & Prevention.

[15]  P. Loehrer.  Multiple Cancer Prevalence: A Growing Challenge in Long-term Survivorship , 2008 .

[16]  Philippe Autier,et al.  Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database , 2010, BMJ : British Medical Journal.

[17]  M. Coleman,et al.  Cancer survival trends in Osaka, Japan: the influence of age and stage at diagnosis. , 2007, Japanese journal of clinical oncology.

[18]  L. Kiemeney,et al.  The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. , 2011, European journal of public health.

[19]  S. Shapiro,et al.  Lead time gained by diagnostic screening for breast cancer. , 1968, Journal of the National Cancer Institute.

[20]  B Rachet,et al.  Survival from bladder cancer in England and Wales up to 2001 , 2008, British Journal of Cancer.

[21]  Franco Berrino,et al.  Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. , 2007, The Lancet. Oncology.

[22]  Janez Stare,et al.  On Estimation in Relative Survival , 2012, Biometrics.

[23]  Gill Lawrence,et al.  Evidence against the proposition that “UK cancer survival statistics are misleading”: simulation study with National Cancer Registry data , 2011, BMJ : British Medical Journal.

[24]  Bernard Rachet,et al.  Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007 , 2013, Thorax.

[25]  L. Ries,et al.  Effect of Changes in Cancer Classification and the Accuracy of Cancer Death Certificates on Trends in Cancer Mortality , 1990, Annals of the New York Academy of Sciences.

[26]  Jacques Ferlay,et al.  International rules for multiple primary cancers. , 2005, Asian Pacific journal of cancer prevention : APJCP.

[27]  B Rachet,et al.  Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study , 2013, British Journal of Cancer.

[28]  R. Hoover,et al.  New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. , 2006 .

[29]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[30]  C. Percy,et al.  Accuracy of cancer death certificates and its effect on cancer mortality statistics. , 1981, American journal of public health.

[31]  E. Sondik.  Measurement of progress against cancer. Extramural Committee to Assess Measures of Progress Against Cancer. , 1990, Journal of the National Cancer Institute.

[32]  Paul W Dickman,et al.  Estimating and modeling the cure fraction in population-based cancer survival analysis. , 2007, Biostatistics.

[33]  B Rachet,et al.  Breast cancer survival and stage at diagnosis in Australia , 2013 .